Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced a licensing agreement with Nizhny Novgorod Chemical Pharmaceutical Plant (Nizhpharm), granting the Russian firm exclusive R&D, regulatory, and commercialization rights to Epidaza (chidamide) across 12 countries and regions in Central Asia and Eastern Europe, including Armenia, Azerbaijan, and Belarus. The deal provides Chipscreen with $29 million total upfront and milestone payments plus high double-digit royalties on net sales.
Royalty upside – high double-digit royalties on sales without commercial investment
First-in-class positioning – only subtype-selective oral HDAC inhibitor in territory
Market Context & Commercial Outlook
Factor
Implication
Target Markets
~150 million population across 12 countries; limited access to innovative oncology therapies due to sanctions and supply constraints
HDAC Inhibitor Class
Vorinostat, romidepsin (non-selective) established but toxic; chidamide’s subtype selectivity offers improved safety profile
Competitive Advantage
Oral administration vs. injectable competitors; immune microenvironment modulation supports combination with PD-1/PD-L1 inhibitors
Pricing Strategy
Expected $15,000–25,000 annual therapy cost – premium to generics but accessible vs. Western innovator pricing
Revenue Potential
Peak sales $50–80 million annually across 12 territories; Chipscreen royalties $10–15 million at maturity
Regulatory Timeline: Nizhpharm filings 2026–2027 leveraging China NMPA approval data; first launches 2028 in priority markets (Belarus, Armenia)
Geopolitical Consideration: Deal navigates sanctions environment via local manufacturing and non-Western supply chain; positions Chipscreen as reliable partner in restricted markets
Forward‑Looking Statements This brief contains forward‑looking statements regarding regulatory approval timelines, commercial launch execution, and royalty projections for Epidaza in Central Asia and Eastern Europe. Actual results may differ due to geopolitical instability, currency fluctuation risks, and competitive dynamics with alternative oncology therapies in emerging markets.-Fineline Info & Tech
By Fineline Cube